# **BMJ Open** Effect of goal-directed mobilisation versus standard care on physical functioning among medical inpatients: the GoMob-in randomised, controlled trial

Fabian D Liechti <sup>(i)</sup>, <sup>1</sup> Jeannelle Heinzmann, <sup>1</sup> Nina A Schmutz, <sup>1</sup> Michael L Rossen, <sup>1</sup> Jean-Benoît Rossel, <sup>2</sup> Andreas Limacher, <sup>2</sup> Joachim M Schmidt Leuenberger, <sup>3</sup> Christine Baumgartner <sup>(i)</sup>, <sup>1</sup> Maria M Wertli <sup>(i)</sup>, <sup>1,4</sup> Drahomir Aujesky, <sup>1</sup> Martin Verra, <sup>3</sup> Carole E Aubert<sup>1,5</sup>

#### To cite: Liechti FD,

Heinzmann J, Schmutz NA, et al. Effect of goal-directed mobilisation versus standard care on physical functioning among medical inpatients: the GoMob-in randomised, controlled trial. BMJ Open 2024;14:e086921. doi:10.1136/ bmjopen-2024-086921

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-086921).

Received 26 March 2024 Accepted 16 October 2024

#### Check for updates

C Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to** Dr Fabian D Liechti: fabian.liechti@insel.ch

# ABSTRACT

Objective To assess the effect of goal-directed mobilisation (GDM) on physical functioning in medical inpatients.

**Design** Randomised, controlled, single-centre, parallel. superiority trial with a 3-month follow-up and blinded outcome assessment.

Setting General internal medicine wards of a Swiss tertiary acute hospital, September 2021 to April 2023. Participants Adults with expected hospitalisation of ≥5 days, physiotherapy prescription and ability to follow study procedures.

Intervention GDM during hospitalisation, which includes personal goal setting and a short session of patient education through a physiotherapist (experimental group), versus standard care (control group).

Outcome measures The primary outcome was the change in physical activity between baseline and day 5 (De Morton Mobility Index (DEMMI)). Secondary outcomes included in-hospital accelerometer-measured mobilisation time; in-hospital falls; delirium; length of stay; change in independence in activities of daily living, concerns of falling and quality of life: falls, readmission and mortality within 3 months.

**Results** The study was completed by 123 of 162 (76%) patients enrolled, with the primary outcome collected at day 5 in 126 (78%) participants. DEMMI Score improved by 8.2 (SD 15.1) points in the control group and 9.4 (SD 14.2) in the intervention group, with a mean difference of 0.3 (adjusted for the stratification factors age and initial DEMMI Score, 95% CI -4.1 to 4.8, p=0.88). We did not observe a statistically significant difference in effects of the interventions on any secondary outcome.

**Conclusions** The patient's physical functioning improved during hospitalisation, but the improvement was similar for GDM and standard of care. Improving physical activity during an acute medical hospitalisation remains challenging. Future interventions should target additional barriers that can be implemented without augmenting resources.

Trial registration number NCT04760392.

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- $\Rightarrow$  We recruited from general internal medicine wards and used broad inclusion criteria to investigate the intervention in a diverse population.
- $\Rightarrow$  The investigation did not use additional resources.
- $\Rightarrow$  Participants were randomised, the primary outcome assessment was blinded and models were adjusted for stratification factors and baseline values.
- $\Rightarrow$  Key limitation is the high number of participants with a hospitalisation shorter than expected and, hence, missing primary outcome assessment.
- $\Rightarrow$  Further, due to randomisation on an individual level, our intervention may also have influenced treatment in the standard care group despite high adherence to the intervention.

# INTRODUCTION

data mining, AI training, Low physical activity during hospitalisation is associated with cascading adverse effects, , and such as falls, depression, institutionalisations, readmissions and mortality.<sup>1-4</sup> While bedrest sim is rarely indicated, medical inpatients still spend a lot of time in bed, with older patients spending up to 80% of the time there.<sup>56</sup> The low level of mobility during hospitalisation can be explained by multiple barriers at patient, healthcare professional, environ- & ment and system levels and the low priority of  $\overline{\mathbf{g}}$ patient mobilisation.78

Interventions aimed at improving mobility during hospitalisation can lead to better outcomes, such as decreased loss of autonomy, falls, costs and length of stay and fewer readmissions and institutionalisations.<sup>9-20</sup> Among those interventions, goal-directed mobilisation (GDM) programmes, where a mobility goal is defined and communicated to the

and

Protected by copyright, including for uses related to text

patients and their treating team, were associated with increased physical activity, but evidence on its benefit remains limited.<sup>19 20</sup> GDM is usually started early during hospitalisation or intensive care treatment, where it has been shown to improve physical activity in selected patient groups.<sup>21 22</sup> A recent review summarised limitations that could explain why broad-scale practice changes and implementation of GDM did not occur: studies aimed at increasing mobility during hospitalisation often required additional staff, follow-up was frequently limited to hospitalisation duration and the studies presented methodological limitations, such as a pre-post design or a small sample size.<sup>21</sup> Also, the effects of GDM in general internal medicine inpatients-a large, quickly growing, and resource-intensive inpatient group, many of whom suffer from chronic diseases and fatigue and are multimorbid and highly complex—is uncertain.<sup>23–25</sup>

To address previous studies' limitations and the evidence gap regarding GDM in a diverse patient population, we conducted the goal-directed mobilisation versus standard care on physical functioning among medical inpatients trial, which tested the effect of a GDM intervention compared with standard care on physical functioning during hospitalisation and other outcomes within 3 months. The GDM programme was developed to not require additional resources.

# **MATERIALS AND METHODS** Study design

We performed a randomised, controlled, single-centre, open-label, parallel, superiority trial with a 3-month follow-up and a blinded outcome assessment, registered before start of recruitment at ClinicalTrials. gov (NCT04760392) and conducted according to the published protocol.<sup>26</sup> Reporting follows the Consolidated Standards of Reporting Trials 2010 statement recommendations.<sup>27</sup> During the consent process, all patients received information on the general aims of the study, randomisation and planned assessments, but not on the specific instructions used in the intervention.

### Patient and public involvement None.

# **Participants**

We enrolled patients aged  $\geq 18$  years, who were hospitalised in the department of general internal medicine, Bern University Hospital (tertiary acute care hospital in Switzerland) and had a physiotherapy prescription. Exclusion criteria were (1) inability to follow study procedures or sign informed consent due to language problems (unable to understand German), psychological disorders, severe dementia<sup>28</sup> or blindness; (2) expected hospital stay<5 days (based on clinical evaluation by the study staff and discussion with a senior physician); (3) medically indicated bedrest or restrictions due to contact precautions for >24 hours; (4) lower extremity deficits

directly impairing walking capacity, for example, after stroke or fracture; (5) terminal illness; (6) pregnancy/ breastfeeding. Compared with the original protocol, we dropped the criterion of only including one patient per room after March 2022 to increase recruitment because patients were often moved to other rooms and staff was not attributed to the same rooms each following day. Baseline characteristics (demographic data, prehospital mobility, De Morton Mobility Index (DEMMI) Score, Barthel Index, Falls Efficacy Scale—International (FES-I) and the 5-level version of the EuroQol EQ-5D question-naire (EQ-5D-5L)) were collected before randomisation. The DEMMI is a 15-item score to measure physical func-Barthel Index, Falls Efficacy Scale—International (FES-I) ş tioning in older hospitalised adults (0, poor physical funccopyright, inc tioning to 100, independent activity) and has a minimal clinically important difference of 5–10 points.<sup>29–31</sup>

### **Randomisation and blinding**

Patients were randomly assigned (1:1) to the experimental or control group, at latest on the second hospitalisation day using the data entry software REDCap (Vanderbilt University, Nashville, Tennessee, USA)<sup>32</sup> with stratification by baseline DEMMI Score (≤40vs >40 points; online uses rela supplemental materials) and age (<65 vs  $\geq 65$  vears old) using varying block sizes of 2, 4 and 6.<sup>29 30</sup> The allocation sequence (randomisation list) was concealed from the study team. All participants and the study team, except physiotherapists assessing the DEMMI and statisticians text responsible for the final analysis, were aware of group assignment after baseline assessment and randomisation.

# Intervention

Intervention The experimental intervention consisted of a GDM programme during hospitalisation. After randomisation, the study team assigned in discussion with the patient the first individual mobility goal. Mobility goals ≥ were adapted from the Johns Hopkins Highest Level of Mobility and used eight levels (1, bed activities; 2, sit at edge of bed; 3, transfer to chair/commode; 4, stand for >1 min; 5, walk≥10 steps; 6, walk≥7.5 m; 7, walk≥75 m; 9 8, walk≥75 m (30 min or stairs) and no bed rest during daytime).<sup>33</sup> Participants were instructed to complete the <u>0</u> mobility goal at least three times per day. The identified individual mobility goal was then depicted on a patient communication board next to the bed, visible for all stakeholders (patients, visiting friends and family, physicians, nurses, physiotherapists; online supplemental table 1). Participants in the intervention group received **g** a leaflet with a guide on importance, aims and imple- 3 mentation of early mobilisation during hospitalisation, including definitions of mobility goals (online supplemental materials). During the first physiotherapy session (at latest on the first working day after study inclusion), a trained physiotherapist provided short education on GDM. The physiotherapist revised the individual mobility goal level, in discussion with the patient and taking into account current mobility capacities, comorbidities and perspectives of recovery. The frequency and total number

and

of physiotherapy sessions was at the discretion of the treating physiotherapists. The number of physiotherapy sessions was retrieved from electronic health records at the end of the study. To avoid using additional resources, that is, increasing the amount of physiotherapy provided, the intervention focussed on indicating a clear goal to increase mobilisation throughout the hospital stay, particularly between physiotherapy sessions, when no specific staff was available. The intervention was formally stopped at hospital discharge, transfer to a unit other than general internal medicine or 15 days after study inclusion. Patient communication boards were removed, and goal setting not anymore actively encouraged, but, if necessary, patients would still receive routine physiotherapy. All healthcare professionals caring for the participant were allowed to adapt the mobility goal level together with the patient at any time-usually to a higher level, but level reductions were also allowed.

The study team instructed nurses and physicians about the trial's aims without using resources not available in everyday practice: before inclusion of the first participant, nurses were instructed by brief oral presentations at their regular meetings and thereafter every 3-4 months and through disseminated handouts. Residents received a brief email at inclusion of a patient to the intervention group. Trained physiotherapists with experience in general internal medicine were instructed at trial inception and thereafter if deemed necessary (eg, for new staff members or after protocol deviations). Protocol adherence was assessed at study visits by presence of the board displaying the mobility goal level and by nurses' and physiotherapists' entries to the electronic health record to detect any protocol deviations.

# **Control intervention and standard care**

All patients in both groups received standard care, including physiotherapy. Regular physiotherapy sessions included individual training and/or group sessions, while the content and frequency were determined by the physiotherapists after initial prescription by a physician according to the patient's abilities and individual goals.

# **Contrasts between interventions**

Mobility goals were not routinely set nor encouraged interprofessionally in the control group and not displayed on the patient communication board. The medical team was not informed about patients recruited to the control group.

# **Outcome measures**

The primary outcome was the change in physical functioning between baseline and day 5±2 days (D5) after enrolment, measured with the DEMMI by trained study staff blinded to group allocation. Shortly before the assessment, patients were instructed not to reveal their group allocation; patient communication boards indicating mobility goals were then removed by nursing staff for the

time of the assessment by the physiotherapist to minimise the risk of revealing group allocation to the assessor.

All participants were equipped with a waterproof, wristworn accelerometer (GENEActiv) to measure three axes of acceleration at a frequency of 50 Hz, allowing uninterrupted data collection for 15 days, along with temperature to verify that the device was worn continuously.<sup>34</sup> The accelerometer has no display because the study's aim was to evaluate implementation of GDM without using additional technological assets, which has already been proven to function, but comes at additional costs.<sup>9 35</sup> The rotected accelerometers were activated when participants were fitted with them and collected by the study team when discharged from the hospital, transferred to a unit other than general internal medicine for longer than 24 hours, or 15 days after study inclusion (end of the intervention) to read out the data. Data were not analysed until they had been fully collected from all participants.

Secondary outcomes collected during the hospital stay or from discharge letters included change in DEMMI between baseline and discharge or day 14±2 days (D14; whichever occurred first, blinded assessment); accelerometer-measured mobilisation time between uses r enrolment and D5, and between enrolment and discharge (blinded assessment); in-hospital falls; delirium; length of stay; and discharge destination (ie, home, rehabilitation clinic, nursing home or palliative care unit or hospital). Secondary outcomes collected by phone interview 3 q months after randomisation included the number of e falls and readmissions; all-cause mortality; and change between enrolment and 3-month follow-up in Barthel Index (0-100 points, higher scores indicate greater independence in activities of daily living),<sup>36</sup> concerns of falling (FES-I, 16–64 points, higher scores indicating higher **E** concern)<sup>37</sup> and quality of life (EQ-5D-5L, mobility dimension (levels 0-5) and Visual Analogue Scale (score 0-100, ≥ higher scores indicating better quality of life)).<sup>38</sup> Mobilisation time was calculated from accelerometer data by a statistician blinded to the group allocation and defined ng, as proportion of time with light, moderate or vigorous physical activity (acceleration>30 mG), disregarding nocturnal sleeping time and the time not wearing the similar technol device (R statistical software, GGIR V.2.9.0).<sup>39</sup>

# **Statistical analysis**

We estimated that a sample size of 64 in each group (total 128 participants) would have a power of 80% to detect a difference in DEMMI change within 5 days of 5 score & points, the minimal clinically important difference, with a SD of 10 points at a two-sided alpha level of 0.05.<sup>29–31 40 41</sup> To account for a dropout of 20%, we increased the sample size to 80 per group (total 160 participants).

Data analysis was conducted according to a prespecified statistical analysis plan (online supplemental materials) by a statistician without access to the group allocation until the primary analysis was finished. The primary intention-to-treat analysis used a linear model to assess changes in DEMMI with adjustments for stratification factors. Secondary continuous outcomes were analysed using the same approach. Quality of life was analysed as the difference between baseline and 3 months in the Visual Analogue Scale and in the mobility dimension of the EQ-5D-5L. Count outcomes were assessed using a negative binomial model, categorical outcomes using a multinomial logistic model, binary outcomes using logistic regression and time-to-event outcomes using a Cox regression model. All analyses were adjusted for the stratification factors; changes from baseline were additionally adjusted for the baseline value.

If outcomes were missing, we employed multiple imputation in the primary analysis, including the subgroup analyses, except for categorical and count outcomes, where only age, sex and body mass index were used in the imputation model. We used multiple imputation by chained equation to impute all variables separately, generating 50 imputed data set as predefined in the statistical analysis plan (online supplemental materials). In a secondary per-protocol analysis, without using imputation for missing values, patients who violated any eligibility criteria, did not receive the allocated intervention or were discharged before day 4 were disregarded.

We performed prespecified subgroup analyses for baseline DEMMI ( $\leq$ 40 vs >40), age (<65 vs  $\geq$ 65 years) and prehospital mobility (no mobility aid vs use of mobility aid), because these variables are associated with lower DEMMI scores.<sup>42 43</sup> All effect measures were accompanied by 95% CI. The statistical testing was two sided with a type 1 error of 5%. Analyses were performed with Stata V.18.0 and R V.4.2.2.

# RESULTS

#### **Study population**

Between 12 September 2021 and 18 January 2023, we enrolled 162 patients among 5744 admissions to our department; 81 were randomised to receive standard care and 81 GDM (flow chart in figure 1). The median age was 72 (IQR 17, range 23–100) years; 97 (60%) participants were men and 73 (45%) used a walking aid before admission. Intervention and control groups were similar at baseline, except for older age and more self-reported depression in the intervention group, but not according to the depression diagnoses reported in the discharge letters (table 1 and online supplemental tables 2 and 3).

#### **Procedural characteristics**

Participants received the intervention or control procedure largely as intended, except in the intervention group where two patients interrupted participation due to new conditions prohibiting mobilisation and in the control group where one patient accidentally received instructions that included goal setting. We did not encounter any relevant serious adverse events. The first personal mobility goals are reported in table 2. The primary outcome was available in 137 patients. In 126 (78%) participants (control group, 61 participants (75%); BMJ Open: first published as 10.1136/bmjopen-2024-086921 on 14 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

intervention group 65 participants (80%)), DEMMI was assessed for the second time on D5. 19 (12%) participants died within the 3-month follow-up and 20 (12%) were lost to follow-up, leaving 123 participants completing the study according to protocol (60 participants in the control, 63 in the intervention group). This included three protocol deviations with one control group patient who accidentally received the intervention, and two intervention group participants who were not eligible because they participated in the study previously in the control group.

group. The estimated discharge date was difficult to predict and the length of stay was shorter than expected in 27 participants (less than 3 days in 17 (21%) control group participants). In 25% of the participants in the control group participants). In 25% of the participants in the control group particand 20% in the intervention group, the primary outcome was assessed outside the intended period (protocol deviations are listed in online supplemental table 4). Mobilisation time was recorded for at least 1 day in 141 (87%) participants. Reasons for failure to record included technical issues and participant's refusal to wear the device. The number of physiotherapy sessions did not differ between groups (in both groups, median 3, IQR 2–5).

### **Primary outcome**

In the full-analysis set with multiple imputation, DEMMI Score improved by 8.2 (SD 15.1) points in the control of and 9.4 (SD 14.2) points in the intervention group, without reaching statistical difference between the two groups (adjusted difference using multiple imputation 0.3, 95% CI –4.1 to 4.8, p=0.88; table 3). The participant's individual DEMMI Score tracks varied considerably, but the proportion of participants with any DEMMI Score improvements was similar between groups (control group, 69%, intervention group 64%, adjusted OR 0.6, 95% CI 0.2 to 1.4, p=0.19; Online supplemental figures 1 and 2). In the full-analysis set of 137 available cases, including those with primary outcome assessment outside the intended time frame of D5, adjusted difference was 0.2 (95% CI –4.3 to 4.8, p=0.92).

### **Secondary outcomes**

No differences in DEMMI scores between study inclusion and discharge were observed. Until both, day 5 and discharge, the mobilisation time measured by accelerometers was similar in the control group and in the intervention group. Length of hospital stay was not influenced by the intervention and the proportion of patients discharged at home was similar in both groups. During the hospital stay, two falls were reported in each of the groups, both without severe complications.

Three months after study inclusion, we did not observe any differences in effect between the intervention and the control group, that is, adjusted differences for change in concerns of falling as measured by the FES-I, the EQ-5D-5L mobility dimension and Visual Analogue Scale did not change. 3-month readmission and mortality




Figure 1 Flow of participants in the goal-directed mobilisation of medical inpatients trial (according to Consolidated Standards of Reporting Trials).

were similar in both groups. Readmission or death within 3 months was observed in 42 of 81 (52%) participants in the intervention group (11 deaths, 32 readmissions) and in 38 of 81 (47%) participants in the control group (eight deaths, 34 readmissions).

# **Secondary analyses**

In the per-protocol analysis, the primary analysis' results of the primary outcome were confirmed (adjusted difference 0.6, 95% CI -4.5 to 5.8, p=0.81). In subgroup analyses, which were prescheduled in the published study protocol but underpowered, we observed a larger difference in participants younger than 65 years old (difference in DEMMI Score 5.0, 95% CI -4.5 to 14.5, p=0.29) compared with those at least 65 years old (-1.5, 95% CI -6.4 to 3.4, p=0.55); we also observed a larger difference in participants not using a mobility aid before admission (4.0, 95% CI -2.5 to 10.4, p=0.22) compared with those needing a mobility aid (-3.1, 95% CI -9.2 to 3.1, p=0.32),

GDM and standard of care on physical functioning levels **3** measured by DEMMI during an acute care hospitalisation. Secondary outcomes-such as mobilisation time, length of hospital stay, discharge destination or 3-month survival-were not significantly influenced by the GDM programme.

Analyses in predefined subgroups revealed possible beneficial effects of GDM in younger participants and those without prior mobility aid; however, these analyses were underpowered and statistically non-significant.

Measures	Standard care (n=81)	Goal-directed mobilisation (n=81)	
Age			
Mean (SD) (years)	70.0 (12.0)	72.6 (14.4)	
Median (IQR) (years)	70 (64–79)	76 (63–82)	
≥65 years old	58 (71.6%)	58 (71.6%)	
Sex (male)	52 (64.2%)	45 (55.6%)	
Body mass index, median (IQR) (kg/m²)	25.5 (22.5–30.8)	24.8 (21.5–29.8)	
Elective admission	7 (8.6%)	5 (6.2%)	
Intensive care before enrolment	5 (6.2%)	10 (12.3%)	
Mobility aid			
None	52 (64.2%)	37 (45.7%)	
Walking stick	12 (14.8%)	19 (23.5%)	
Walking frame	17 (21.0%)	25 (30.9%)	
Fall(s) during last 6 months			
None	53 (65.4%)	47 (58.0%)	
1–2	16 (19.8%)	22 (27.2%)	
>2	12 (14.8%)	12 (14.8%)	
De Morton Mobility Index Score (range 0–100 points)			
Mean (SD)	58.8 (23.4)	55.5 (22.9)	
Median (IQR)	62 (41–74)	57 (41–74)	
≤40 points	19 (23.5%)	19 (23.5%)	
Falls Efficacy Scale (range 16–64 points), median (IQR)	22 (16–31)	22 (17–30)	
EQ-5D-5L			
Mobility dimension (range 0–5), median (IQR)	2 (1–3)	3 (1–4)	
Visual Analogue Scale (range 0–100), median (IQR)	50 (39–68)	50 (40–70)	
Barthel Index (range 0–100), median (IQR)	100 (90–100)	95 (80–100)	

Data are median with IQR, mean with SD, or number with percentage.

EQ-5D-5L, 5-level version of the EuroQol EQ-5D questionnaire

The finding that younger patients may profit more from GDM may be explained by the increasing proportion of cognitive impairment usually observed in older people, while patients' prehospital use of mobility aids possibly indicates long-term mobility deficits.<sup>44</sup> People with such impairments might need additional resources to improve

 
 Table 2
 First personal mobility goals of participants in the
 intervention group (baseline visit) Level Mobility goal N (%) 1 Bed activities 8 (9.9%) 2 Sit at edge of bed 7 (8.6%) 3 Transfer to chair/commode 2 (2.5%) 4 Stand for >1 min 6 (7.4%) 5 Walk≥10 steps 11 (13.6%) 6 Walk≥7.5m 18 (22.2%) 7 Walk≥75m 29 (35.8%) 8 Walk≥75 m (30 min or stairs) 0 (0%)

physical activity or functioning. However, it is possible that they benefited from GDM, but recovery was too slow to be recorded.

Our negative findings contrast with results of small randomised trials.<sup>13 15</sup> However, studies in medical wards using goal setting suffered methodological issues and failed to demonstrate positive long-term effects, and the only beneficial short-term effect consistently reported across studies was an increase in physical activity.<sup>21</sup> Additionally, publication bias may play a role, as the number of studies with a randomised design in this field is generally low and funnel plot asymmetry is typical.<sup>45</sup> Several factors may explain why GDM did not increase physical functioning.

First, the intervention might work for a specific subgroup of patients only, for example, younger patients or those with less comorbidities or complexity, as shown in the subgroup analysis. Individual trajectories of our participants indeed varied considerably. In such a heterogeneous population recruited with various ages and levels of morbidity, multiple barriers and facilitators should

Table 3      Primary and secondary outcome measures are shown as unadjusted values with missing data imputed (means with	
SD, proportions or median survival times)	

Measures	Standard of ca (n=81)	are Goal-directed mobilisation (n=81	Adjusted effect ) estimate (95% CI)*	P value
Change in De Morton Mobility Index (DEMMI) Score				
Baseline to day 5 (MD)	8.2 (15.1)	9.4 (14.2)	0.3 (-4.1 to 4.8)	0.88
Baseline to discharge (MD)	9.0 (15.9)	9.9 (14.4)	-0.1 (-4.7 to 4.5)	0.97
Improvement (baseline to day 5) (OR)	69.3%	63.7%	0.6 (0.2 to 1.4)	0.19
Mobilisation time, daily proportion of time spent activ	/e, measured by	accelerometer (%)		
Until day 5 (MD)	13.4 (7.6)	14.9 (9.1)	1.5 (-1.1 to 4.2)	0.26
Until discharge (MD)	13.4 (7.6)	15.0 (9.2)	1.6 (-1.0 to 4.3)	0.23
Number of in-hospital falls (IRR)	0.0 (0.2)	0.0 (0.2)	1.0 (0.1 to 7.1)	1.00
In-hospital delirium (OR)	4.9%	6.2%	1.3 (0.3 to 5.0)	0.73
Length of stay, median (IQR) (HR)	5 (4, 9)	5 (4, 8)	1.0 (0.8 to 1.4)	0.86
Discharge destination (RR)			1.4 (0.7 to 2.7)	0.38
Home	60.0%	61.7%	1	Ref.
Rehabilitation clinic	15.3%	13.4%	0.8 (0.3 to 2.3)	0.75
Nursing home or palliative care	10.4%	8.1%	0.8 (0.2 to 2.5)	0.64
Other hospitals	14.3%	16.9%	1.1 (0.4 to 3.1)	0.80
Outcomes within 3 months				
Number of falls (IRR)	0.3 (0.8)	0.7 (2.4)	1.8 (0.8 to 3.9)	0.13
Number of readmissions (IRR)	0.7 (1.0)	0.7 (1.2)	0.9 (0.6 to 1.5)	0.79
All-cause mortality, cumulative incidence (95% Cl) (HR)	10.6% (5.4% t 20.1%)	o 11.1% (5.9% to 20.3%)	1.1 (0.4 to 2.9)	0.80
Change from baseline to telephone interview†				
Barthel Index (range 100–0) (MD)	1.0 (18.5)	3.9 (23.9)	-0.3 (-6.0 to 5.5)	0.93
Falls Efficacy Scale (range 16–64 points) (MD)	-1.4 (9.6)	-2.9 (10.5)	-0.8 (-3.5 to 1.8)	0.54
EQ-5D-5L, Mobility Dimension (range 1–5) (MD)	-0.4 (1.5)	-0.5 (1.3)	0.0 (-0.4 to 0.4)	0.93
EQ-5D, Visual Analogue Scale (range 0-100) (MD)	9.6 (24.6)	7.2 (23.7)	-0.9 (-7.9 to 6.1)	0.81
Improvement in Barthel score (OR)	30.1%	37.5%	1.1 (0.5 to 2.6)	0.89
EQ-5D-5L, 5-level version of the EuroQol EQ-5D questionnation $\mathbb{R}^*$ Mean differences (MD), incidence rate ratios (IRR), relative points vs >40 points and age (<65 vs ≥65 years), changes fr †At 3 months.	risk ratios (RR), O			ore (≤40
be addressed together—but this often require esources. Second, the time window may have been to or an effective intervention, for example, in a p tudy, physical activity increased only after the th of a GDM intervention, while a meta-analysis m ncreasing effectiveness after admission until 2 wee lischarge. <sup>17 46</sup> With the length of hospital stay be horter, the time being physically active (meas	ph o short 7 orevious en- hird day the odelled the eks after exp coming gos	al-setting mobilisation c ysical activity. Third, our intervention ough to change partic e high-level standard o erapy offered to all par pected baseline DEMM als, we added one leve stairs) and no bed rest	n may not have bee ipants' behaviour, be f care with individua ticipants and the hig I scores. <sup>47 48</sup> For the l (level 8, walk≥75 n	en stron ecause c al physic gher that e mobilit n (30 mit

Second, the time window may have been too short for an effective intervention, for example, in a previous study, physical activity increased only after the third day of a GDM intervention, while a meta-analysis modelled increasing effectiveness after admission until 2 weeks after discharge.<sup>17 46</sup> With the length of hospital stay becoming shorter, the time being physically active (measured as proportion of hospitalisation time) may remain low, despite improving physical activity.<sup>6</sup> This can be explained by both the patients' enfeeblement due to their presenting complaints and time-consuming investigations and treatments mostly during the beginning of hospitalisation. Nevertheless, 40% of our participants were transferred to another institution (eg, hospital, rehabilitation centre or a nursing home) after their index hospitalisation, where a

goals, we added one level (level 8, walk≥75 m (30 min 8 or stairs) and no bed rest during daytime) to the Johns Hopkins Highest Level of Mobility (JH-HLM) scale because we expected that most patients would qualify for level 7 (walk $\geq$ 75 m, corresponding to around 100 steps).<sup>33</sup> Level 8 is in line with studies using goals of 5000 steps or physical activity for more than 30 min, but may not have been clear enough.<sup>35 46 49</sup> In our study, more than one-third of participants were initially assigned to level 7, but none to level 8. In our experience, patients on level

8 are often guickly discharged, possibly also reflected in the short length of stay of around 5 days.<sup>35 46</sup> Some study procedures such as measuring time mobilised with a wristworn device may have influenced mobility in both arms and thereby reduced differences between groups.<sup>50 51</sup> Reaching a certain level of mobility may also have triggered discharge from hospital and biased mobilisation time, which did not differ between groups.

We aimed not to use additional resources. Nevertheless, should GDM prove to reduce the length of hospital stay, the deployment of additional personnel could still be deemed cost-effective. In the present study, however, no reduction in length of stay was observed. As most studies employed pre-post designs and that the length of stay is generally decreasing, the beneficial effect of GDM on this outcome remains uncertain.<sup>19 21 35</sup> Previously, long-term effects of GDM interventions were only seldom investigated with only one study showing a beneficial effect on Life-Space Assessment.<sup>12</sup><sup>21</sup> With no evidence of shortterm effects, it is also not surprising that we did not find any differences in the 3-month outcomes, such as quality of life. The study was also not powered to identify such differences. Remarkably, half of the participants were readmitted or died within 3 months, not only highlighting the vulnerability of the population investigated but also indicating that other factors, particularly comorbidities, may weigh more in terms of severe outcomes.

The study has several strengths. First, we used a randomised design to reduce selection bias and confounding. Potential remaining variation in important baseline characteristics was addressed by adjusting the models for stratification factors and baseline values for differences, which were defined a priori. Thus, some imbalances in certain variables may still be found. Second, outcome assessment was blinded to reduce information bias; however, double blinding was not feasible for our research question. Contamination and performance bias may still have occurred in this single blinded study; for example, nurses and physiotherapists could be treating participants in both groups. However, less than 4% of all admitted patients were included in the study and participants in the control group could only be recognised by wearing the accelerometer, which was also used for other studies, was worn like a watch and did not have any display. The intervention did not directly target nursing staff; nevertheless, the intervention could have further improved the already high level of standard care and thus weakened the observable effect. Third, by including patients from general internal medicine wards, we investigated the intervention in a diverse population of hospitalised patients, for example, in terms of age and DEMMI, thus enhancing external validity. Finally, in contrast to previous studies, we investigated an intervention that does not require additional resources that would not be available in clinical practice.<sup>12–14 21</sup>

The study also has some limitations, which may explain why we could not detect a clinically meaningful effect of GDM, compared with standard care. First, despite efforts,

primary outcome assessment was missing in around 15% of participants. This was mainly a consequence of a shorter-than-expected length of hospital stay in many participants,<sup>30 40 52</sup> despite having excluded patients with an expected stay of less than 5 days. However, there are no reliable tools to predict length of hospital stay, and analysing the change in physical functioning between admission and hospital discharge would have introduced bias.<sup>53 54</sup> Second, it is possible that the intervention had uncontrolled effects on the standard-of-care group, T for example, by modifying physiotherapist practices. However, the proportion of study participants compared with all patients hospitalised was small and the number of physiotherapists high, making spillover effects unlikely. Third, we assessed adherence by checking electronic opyright including personal mobility goals. Clinical implications and conclusion In our trial, GDM, which fostered mobility without requiring additional resources that might not be avail-

requiring additional resources that might not be available in everyday clinical practice, did not improve physical functioning or mobilisation time. Subgroup analyses suggest that younger patients and those without previous mobility impairments could benefit from goal setting, which can easily complement routine physiotherapy and be part of an interdisciplinary approach to improve mobility. However, eventually, reinforcement of patient mobility takes time-probably more in those with preexisting impairments and older patients.

To conclude, improving physical functioning and mobility during an acute medical hospitalisation with a pre-existing high level of care and short lengths of stay remains challenging. Future interventions should target additional barriers that can be modified with resources that are available in everyday practice and investigate how **@** to specifically improve mobility in different subgroups of  $\geq$ patients.

#### Author affiliations

<sup>1</sup>Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>2</sup>CTU Bern, Department of Clinical Research, University of Bern, Bern, Switzerland <sup>3</sup>Department of Physiotherapy, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>4</sup>Department of General Internal Medicine, Kantonsspital Baden, Baden, Switzerland <sup>5</sup>Institute for Primary Healthcare, University of Bern, Bern, Switzerland

Acknowledgements The authors thank Nicolas Thalmann for helping with data collection, Damiana Pulfer for giving excellent technical support, Gerhard Luder on developing the study design and the involved nursing and physiotherapy teams for implementing the study in their daily care routine.

Contributors FDL: conceptualisation, methodology, validation, formal analysis, investigation, resources, data curation, writing-original draft, writing, review and editing, supervision, project administration, funding acquisition. JMSL: conceptualisation, investigation, resources, writing-review and editing, funding acquisition. JH and NAS: validation, formal analysis, investigation, writingoriginal draft, writing-review and editing. MLR: validation, formal analysis, investigation, writing-review and editing. J-BR: methodology, software, validation, formal analysis, data curation, writing-reviewing and editing, visualisation, AL: methodology, software, validation, formal analysis, data curation, writingreviewing and editing, supervision. CB and MMW: conceptualisation, methodology,

formal analysis, writing—reviewing and editing, supervision. DA: conceptualisation, formal analysis, resources, writing—reviewing and editing, supervision. MV: conceptualisation, investigation, resources, writing—review and editing. CEA: formal analysis, writing—original draft, writing—reviewing and editing, supervision. MV and CEA contributed equally as co-last authors. FDL is the guarantor of the study, accepts full responsibility for the finished work and/or the conduct of the study, had access to the data and controlled the decision to publish.

**Funding** The GoMob-in trial was funded by the Swiss Society of General Internal Medicine Foundation, Bern, Switzerland (grant number: not applicable), the Fondation Sana, Bern, Switzerland (grant number: GF 2021-0048) and Physioswiss, Swiss Association of Physiotherapy, Sursee, Switzerland (grant number: not applicable). FDL and CEA were supported by the Swiss National Science Foundation (grant numbers: P500PM\_206639 for FDL and PZ00P3\_201672 for CEA). The funders had no role in study design, data collection, data analysis, data interpretation, writing of the manuscript and the decision to submit.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

**Ethics approval** The study complied with the Declaration of Helsinki and the guidelines for Good Clinical Practice, and was approved by the local ethics committee (Kantonale Ethikkommission Bern, registration ID 2020-02305, February 2021). Written informed consent to participate was obtained from all participants before taking part in the study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The datasets generated during and/or analysed during the current study are not publicly available as they contain potentially sensitive patient information and we did not obtain consent from participants to make data publicly available, but non-identifiable, individual-level data are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Author note MV and CEA are joint last authors.

#### **ORCID** iDs

Fabian D Liechti http://orcid.org/0000-0003-1006-6903 Christine Baumgartner http://orcid.org/0000-0003-2296-9632 Maria M Wertli http://orcid.org/0000-0001-6347-0198

# REFERENCES

- 1 Creditor MC. Hazards of hospitalization of the elderly. *Ann Intern Med* 1993;118:219–23.
- 2 Brown CJ, Friedkin RJ, Inouye SK. Prevalence and outcomes of low mobility in hospitalized older patients. *J Am Geriatr Soc* 2004;52:1263–70.
- 3 Zisberg A, Shadmi E, Sinoff G, et al. Low mobility during hospitalization and functional decline in older adults. J Am Geriatr Soc 2011;59:266–73.
- 4 Kalisch BJ, Lee S, Dabney BW. Outcomes of inpatient mobilization: a literature review. *J Clin Nurs* 2014;23:1486–501.
- 5 Brown CJ, Redden DT, Flood KL, *et al.* The underrecognized epidemic of low mobility during hospitalization of older adults. *J Am Geriatr Soc* 2009;57:1660–5.

- 6 Valkenet K, Bor P, van Delft L, et al. Measuring physical activity levels in hospitalized patients: a comparison between behavioural mapping and data from an accelerometer. *Clin Rehabil* 2019;33:1233–40.
- 7 Mani H, Möri C, Mattmann M, *et al.* Barriers and facilitators to mobility of patients hospitalised on an acute medical ward: a systematic review. *Age Ageing* 2022;51:afac159.
- 8 Greysen SR. Activating Hospitalized Older Patients to Confront the Epidemic of Low Mobility. *JAMA Intern Med* 2016;176:928–9.
- 9 Cohen Y, Zisberg A, Chayat Y, et al. Walking for Better Outcomes and Recovery: The Effect of WALK-FOR in Preventing Hospital-Associated Functional Decline Among Older Adults. J Gerontol A Biol Sci Med Sci 2019;74:1664–70.
- 10 Liu B, Moore JE, Almaawiy U, et al. Outcomes of Mobilisation of Vulnerable Elders in Ontario (MOVE ON): a multisite interrupted time series evaluation of an implementation intervention to increase patient mobilisation. Age Ageing 2018;47:112–9.
- 11 Fisher SR, Graham JE, Ottenbacher KJ, et al. Inpatient Walking Activity to Predict Readmission in Older Adults. Arch Phys Med Rehabil 2016;97:S226–31.
- 12 Brown CJ, Foley KT, Lowman JD Jr, et al. Comparison of Posthospitalization Function and Community Mobility in Hospital Mobility Program and Usual Care Patients: A Randomized Clinical Trial. JAMA Intern Med 2016;176:921–7.
- Hamilton AC, Lee N, Stilphen M, et al. Increasing Mobility via Inhospital Ambulation Protocol Delivered by Mobility Technicians: A Pilot Randomized Controlled Trial. J Hosp Med 2019;14:272–7.
  Hastings SN, Sloane R, Morey MC, et al. Assisted early mobility
- 14 Hastings SN, Sloane R, Morey MC, et al. Assisted early mobility for hospitalized older veterans: preliminary data from the STRIDE program. J Am Geriatr Soc 2014;62:2180–4.
- 15 Moreno NA, de Aquino BG, Garcia IF, et al. Physiotherapist advice to older inpatients about the importance of staying physically active during hospitalisation reduces sedentary time, increases daily steps and preserves mobility: a randomised trial. J Physiother 2019;65:208–14.
- 16 Raymond MJM, Jeffs KJ, Winter A, et al. The effects of a highintensity functional exercise group on clinical outcomes in hospitalised older adults: an assessor-blinded, randomisedcontrolled trial. Age Ageing 2017;46:208–13.
- 17 Teodoro CR, Breault K, Garvey C, *et al.* STEP-UP: Study of the Effectiveness of a Patient Ambulation Protocol. *Medsurg Nurs* 2016;25:111–6.
- 18 Wood W, Tschannen D, Trotsky A, et al. A mobility program for an inpatient acute care medical unit. Am J Nurs 2014;114:34–40.
- 19 Hoyer EH, Friedman M, Lavezza A, *et al.* Promoting mobility and reducing length of stay in hospitalized general medicine patients: A quality-improvement project. *J Hosp Med* 2016;11:341–7.
- 20 Klein LM, Young D, Feng D, et al. Increasing patient mobility through an individualized goal-centered hospital mobility program: A quasi-experimental quality improvement project. *Nurs Outlook* 2018;66:254–62.
- 21 Heinzmann J, Baumgartner C, Liechti FD. Goal-Directed Mobility of Medical Inpatients-A Mini Review of the Literature. *Front Med* (*Lausanne*) 2022;9:878031.
- 22 Bergbower EAS, Herbst C, Cheng N, *et al.* A novel early mobility bundle improves length of stay and rates of readmission among hospitalized general medicine patients. *J Community Hosp Intern Med Perspect* 2020;10:419–25.
- 23 Verma AA, Guo Y, Kwan JL, et al. Patient characteristics, resource use and outcomes associated with general internal medicine hospital care: the General Medicine Inpatient Initiative (GEMINI) retrospective cohort study. CMAJ Open 2017;5:E842–9.
- 24 Nardi R, Scanelli G, Corrao S, *et al.* Co-morbidity does not reflect complexity in internal medicine patients. *Eur J Intern Med* 2007;18:359–68.
- 25 Liechti FD, Beck T, Ruetsche A, et al. Development and validation of a score to assess complexity of general internal medicine patients at hospital discharge: a prospective cohort study. BMJ Open 2021;11:e041205.
- 26 Liechti FD, Heinzmann J, Schmidt Leuenberger JM, et al. Effect of goal-directed mobilisation intervention compared with standard care on physical activity among medical inpatients: protocol for the GoMob-in randomised controlled trial. *BMJ Open* 2022;12:e058509.
- 27 Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.
- 28 Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–9.
- 29 de Morton NA, Davidson M, Keating JL. The de Morton Mobility Index (DEMMI): an essential health index for an ageing world. *Health Qual Life Outcomes* 2008;6:63.

# **Open access**

- 30 de Morton NA, Davidson M, Keating JL. Validity, responsiveness and the minimal clinically important difference for the de Morton Mobility Index (DEMMI) in an older acute medical population. *BMC Geriatr* 2010;10:72.
- 31 Zupanc A, Vidmar G, Novak P, et al. Feasibility of de Morton Mobility Index for adult patients of all ages at low and basic functioning level: a study using the Slovenian translation. Int J Rehabil Res 2019;42:352–7.
- 32 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
- 33 Hoyer EH, Young DL, Klein LM, *et al.* Toward a Common Language for Measuring Patient Mobility in the Hospital: Reliability and Construct Validity of Interprofessional Mobility Measures. *Phys Ther* 2018;98:133–42.
- 34 Esliger DW, Rowlands AV, Hurst TL, et al. Validation of the GENEA Accelerometer. Med Sci Sports Exerc 2011;43:1085–93.
- 35 van Grootel J, Bor P, Netjes JA, et al. Improving physical activity in hospitalized patients: The preliminary effectiveness of a goal-directed movement intervention. *Clin Rehabil* 2023;37:1501–9.
- 36 Richards SH, Peters TJ, Coast J, et al. Inter-rater reliability of the Barthel ADL index: how does a researcher compare to a nurse? Clin Rehabil 2000;14:72–8.
- 37 Yardley L, Beyer N, Hauer K, et al. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing 2005;34:614–9.
- 38 EuroQol G. EuroQol a new facility for the measurement of healthrelated quality of life. *Health Policy* 1990;16:199–208.
- 39 Hees V, Migueles J, Fang Z, et al. GGIR: Raw accelerometer data analysis. 2023.
- 40 Karlsen A, Loeb MR, Andersen KB, et al. Improved Functional Performance in Geriatric Patients During Hospital Stay. Am J Phys Med Rehabil 2017;96:e78–84.
- 41 Oestergaard AS, Mathiesen MH, Karlsen A, et al. In acutely admitted geriatric patients, offering increased physical activity during hospitalization decreases length of stay and can improve mobility. *Transl Sports Med* 2018;1:46–53.
- 42 Macri EM, Lewis JA, Khan KM, *et al.* The de morton mobility index: normative data for a clinically useful mobility instrument. *J Aging Res* 2012;2012:353252.
- 43 Melgaard D, Rodrigo-Domingo M, Mørch MM, et al. DEMMI Scores, Length of Stay, and 30-Day Readmission of Acute Geriatric Patients

in Denmark: A Cross-Sectional Observational Study with Longitudinal Follow-Up. *Geriatrics (Basel)* 2019;4:8.

- 44 Gillis C, Mirzaei F, Potashman M, *et al.* The incidence of mild cognitive impairment: A systematic review and data synthesis. *Alzheimers Dement (Amst)* 2019;11:248–56.
- 45 Cortes OL, Delgado S, Esparza M. Systematic review and meta-analysis of experimental studies: In-hospital mobilization for patients admitted for medical treatment. *J Adv Nurs* 2019;75:1823–37.
- 46 Gallardo-Gómez D, Del Pozo-Cruz J, Pedder H, et al. Optimal dose and type of physical activity to improve functional capacity and minimise adverse events in acutely hospitalised older adults: a systematic review with dose-response network meta-analysis of randomised controlled trials. *Br J Sports Med* 2023;57:1272–8.
- 47 D'Souza AN, Granger CL, Kay JE, et al. Physical activity is low before and during hospitalisation: A secondary observational study in older Australian general medical patients. *Australas J Ageing* 2023;42:545–53.
- 48 Hartley P, Romero-Ortuno R, Wellwood I, et al. Changes in muscle strength and physical function in older patients during and after hospitalisation: a prospective repeated-measures cohort study. Age Ageing 2021;50:153–60.
- 49 Yamashita M, Kamiya K, Hamazaki N, et al. Effects of Acute Phase Intensive Physical Activity (ACTIVE-PA) Monitoring and Education for Cardiac Patients: Pilot Study of a Randomized Controlled Trial. J Med Internet Res 2023;25:e42235.
- 50 Clemes SA, Parker RAA. Increasing our understanding of reactivity to pedometers in adults. *Med Sci Sports Exerc* 2009;41:674–80.
- 51 König LM, Allmeta A, Christlein N, *et al.* A systematic review and meta-analysis of studies of reactivity to digital in-themoment measurement of health behaviour. *Health Psychol Rev* 2022;16:551–75.
- 52 Liechti FD, Bütikofer L, Mancinetti M, et al. Factors associated with one-year mortality after hospital discharge: A multicenter prospective cohort study. *PLoS One* 2023;18:e0288842.
- 53 Lequertier V, Wang T, Fondrevelle J, et al. Hospital Length of Stay Prediction Methods: A Systematic Review. *Med Care* 2021;59:929–38.
- 54 Stone K, Zwiggelaar R, Jones P, *et al.* A systematic review of the prediction of hospital length of stay: Towards a unified framework. *PLOS Digit Health* 2022;1:e0000017.